FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 07:15:42 26/06/2024 pm IST | ||
| 6.04 EUR | -1.31% |
|
| Current month | -16.96% | ||
| 1 month | -18.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 6.04 | -1.31% |
| 25/24/25 | 6.12 | +4.44% |
| 24/24/24 | 5.86 | -6.24% |
| 21/24/21 | 6.25 | +0.97% |
| 20/24/20 | 6.19 | -4.18% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 07:15 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33LG |
| ISIN | DE000HD33LG9 |
| Date issued | 27/02/2024 |
| Strike | 568.6 $ |
| Maturity | Unlimited |
| Parity | 15.75 : 1 |
| Emission price | 10.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.3 € |
|---|---|
| Lowest since issue | 5.25 € |
| Spread | 0.02 € |
| Spread % | 0.34% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
